Inhaled Albuterol and Oral Prednisone Therapy in Hospitalized Adult Asthmatics: Results (1)

Inhaled Albuterol and Oral Prednisone Therapy in Hospitalized Adult Asthmatics: Results (1)Of the 44 patients who entered the study, 39 were followed to the completion of the investigation. Two patients with prior history of intensive care unit admissions for asthma and intubation became severely ill and were transferred to the ICU where they recovered after several days. Both patients had been randomized to the aminophylline group. Three patients were discharged against medical advice. Data analysis was performed for the 39 patients who completed the study. Three of the 39 patients who finished the study were entered twice and crossed over to the opposite treatment on readmission (ie, 36 patients were analyzed for 39 admissions). The mean length of time between admission for these three patients was 5.6 months (range four to eight months).
There were no significant differences in baseline admission characteristics between the placebo and aminophylline groups (Table 1). Percent predicted spirometric values before and after albuterol treatments are shown in Figures 1 to 3 for both groups. We limited our repeated measures A NOVA to the 19 patients with complete data sets through 32 hours (Fig 1 to 3).

Table 1—Characteristics of Patients at Entry into the Study

Placebo, n= 18 Theophylline, n = 21 p value
Age, yr 31.3± 1.4 32.8 ±1.8 0.52
Sex, M or F 11 F, 7 M 9 F, 12 M
Weight, kg 82.3 ±6.7 78.9±4.6 0.68
Height, cm 166.2 ±2.6 169.8 ±2.5 0.32
Childhood onset 11 13
Adult onset 7 8
Serum theophylline
concentration, jig/ml 4.1± 1.1 5.3± 1.3 0.49
FVC, % predicted 63 ±3.9 64.7±3.8 0.75
FEV,, % predicted 41.5±2.8 34.7±2.3 0.08
FEF25-75, % predicted 18.4± 1.7 15.0 ±1.6 0.15
pH 7.37 ±0.009 7.37 ±0.008 .63
Po2, mm Hg 71.5±3.9 76.1 ±3.7 .29
Pco2, mm Hg 35.5± 1.2 35.1 ±0.89 .88

Figure-1

Figure 1. FEV, before and after nebulized albuterol. No significant difference was observed between the groups at any time point (N = 19).

Figure-2

Figure 2.FVC before and after nebulized albuterol. No significant difference was observed between the groups at any time point (N = 19).

Figure-3

Figure 3. FEF25-75 before and after nebulized albuterol. No significant difference was observed between the groups at any time point (N = 19).

This entry was posted in Asthma and tagged , , , .